2015 Fiscal Year Final Research Report
The relationship between the efficacy and the prevalence of the mutant virus for the novel anti-viral drugs for hepatitis C
Project/Area Number |
25460994
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Gastroenterology
|
Research Institution | Osaka University |
Principal Investigator |
hiramatsu naoki 大阪大学, 医学(系)研究科(研究院), 准教授 (30362700)
|
Co-Investigator(Kenkyū-buntansha) |
OZE tsugiko 大阪大学, 大学院医学系研究科, 寄附講座助教 (30623582)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Keywords | 薬剤耐性変異 / C型肝炎 / DAA治療 |
Outline of Final Research Achievements |
Factors associated with the treatment effect,including RAVs in the NS3 region, were examined in 21 patients with genotype 1b HCV infection who were treated with SMV-based therapy after failure of TVR-based therapy. The SVR rate was 50% (10/20,PPS).Ultra-deep sequencing at the start of SMV-based therapy revealed that TVR-resistant variants were detected in 6 patients (29%),and no variants at position 168 were observed. Cross-resistant variants between TVR and SMV were detected in only one patient(SVR).Higher SVRs for SMV-based therapy were attained in relapsers to prior Peg-IFN plus RBV therapy (relapsers 100% vs non-responders 20%, p = 0.007). In this study, ultra-deep sequencing analysis revealed that TVR and/or SMV-resistant variants may have no influence on the effect of SMV-based therapy after failure of TVR-based therapy. Relapsers to previous Peg-IFN/RBV therapy would be a good candidate for retreatment with SMV-based triple therapy.
|
Free Research Field |
C型肝炎
|